American Medical Association (AMA). Opioid Task Force 2020 Progress Report. 2020. Published December 31, 2020. Accessed February 10, 2021. https://www.ama-assn.org/system/files/2020-07/opioid-task-force-progress-report.pdf
Centers for Medicare and Medicaid Services (CMS). Centers For Medicare & Medicaid Services (CMS) Opioid Misuse Strategy 2016. Published January 5, 2017. Accessed February 5, 2021. https://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/CMS-Opioid-Misuse-Strategy-2016.pdf
Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of chronic pain and high-impact chronic pain among adults -- United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:1001-1006.
Department of Health and Human Services. Naloxone: The Opioid Reversal Drug That Saves Lives. Published December 2018. Accessed February 5, 2021. https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.
EVZIO® (naloxone hydrochloride injection) auto-injector [prescribing information]. kaleo, Inc. Approved 1971. Revised October 2016. Accessed February 7, 2021.
Food and Drug Administration (FDA). Approved Drug Products With Therapeutic Equivalence Evaluations, 14th Edition. Published 2021. Accessed February 7, 2021. https://www.fda.gov/media/71474/download
Food and Drug Administration (FDA). FDA Recommends Health Care Professionals Discuss Naloxone With All Patients When Prescribing Opioid Pain Relievers or Medicines to Treat Opioid Use Disorder. Drug Safety Communication. Issued July 23, 2020. Accessed February 23, 2021. https://www.fda.gov/media/140360/download
Green TC, Davis C, Xuan Z, et al. Laws mandating coprescription of naloxone and their impact on naloxone prescription in five US states, 2014-2018. Am J Public Health. 2020;110:881-887.
Guy GP Jr, Haegerich TM, Evans ME, et al. Vital signs: pharmacy-based naloxone dispensing - United States, 2012-2018. MMWR Morb Mortal Wkly Rep. 2019;68:679-686.
Haffajee RL, Cherney S, Smart R. Legal requirements and recommendations to prescribe naloxone. Drug Alcohol Depend. 2020;209:107896.
Madras BK. The President's Commission on Combating Drug Addiction and the Opioid Crisis: origins and recommendations. Clin Pharmacol Ther. 2018;103:943-945.
Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16:769-780.
Narcan (naloxone hydrochloride) nasal spray: instructions for use. Issued August 2020. Accessed February 7, 2021. https://www.narcan.com/static/Gen2-Instructions-For-Use.pdf
NARCAN® (naloxone hydrochloride) nasal spray [prescribing information]. Adapt Pharma, Inc. Approved 1971. Revised August 2020.
National Institute on Drug Abuse. Naloxone. Updated September 2019. Accessed March 4, 2021. https://www.drugabuse.gov/publications/drugfacts/naloxone
National Library of Medicine. Naloxone hydrochloride. Updated March 6, 2021. Accessed January 27, 2021. https://pubchem.ncbi.nlm.nih.gov/#query=naloxone%20hydrochloride
Office of the Surgeon General. U.S. Surgeon General’s Advisory on naloxone and opioid overdose. Updated April 5, 2018. Accessed January 27, 2021. https://www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/index.html
Park TW, Lin LA, Hosanagar A, et al. Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy. J Addict Med. 2016;10:369-381.
Rooney BL, Voter MT, Eberlein CM, et al. Mapping drug overdose demographic and socioeconomic characteristics in the community. WMJ. 2018;117:18-23.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9:63-88.
Sohn M, Brinkman R, Wellman GS. Coprescription of opioid and naloxone in office-based practice and emergency department settings in the United States. Public Health. 2020;180:82-84.
Sohn M, Talbert JC, Huang Z, et al. Association of naloxone coprescription laws with naloxone prescription dispensing in the United States. JAMA Netw Open. 2019;2:e196215.
Stokes A, Berry KM, Collins JM, et al. The contribution of obesity to prescription opioid use in the United States. Pain. 2019;160:2255-2262.
Vivolo-Kantor AM, Hoots BE, Scholl L, et al. Nonfatal drug overdoses treated in emergency departments - United States, 2016-2017. MMWR Morb Mortal Wkly Rep. 2020;69:371-376.
Washington State Department of Health. 2018 Washington State Opioid Prescribing Requirements for Advanced Registered Nurse Practitioners. Updated October 2019. Accessed February 23, 2021. https://www.doh.wa.gov/Portals/1/Documents/9220/631074-PrescriberHandout-ARNP.pdf
Washington State Department of Health. 2018 Washington State Opioid Prescribing Requirements for Osteopathic Physicians & Osteopathic Physician Assistants. Updated October 2018. Accessed February 23, 2021. https://drugpreventionspokane.org/wp-content/uploads/2019/08/osteopathic.pdf
Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6:20-31.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Steven Stanos, DO

Pain Medicine Specialist
Swedish Health System
Swedish Pain Services
Seattle, Washington

Disclosures

Disclosure: Steven Stanos, DO, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Emergent BioSolutions; Hisamitsu; Lilly; Pfizer; Vertex

Panelists

Kathleen Hanley, MD

Associate Professor
Department of Medicine
NYU Grossman School of Medicine
New York, New York

Disclosures

Disclosure: Kathleen Hanley, MD, has disclosed no relevant financial relationships.

Kevin L. Zacharoff, MD

Faculty and Clinical Instructor
Course Director of Pain and Addiction
Department of Family, Population, and Preventive Medicine
Renaissance School of Medicine at Stony Brook University
Stony Brook, New York

Disclosures

Disclosure: Kevin L. Zacharoff, MD, has disclosed no relevant financial relationships.

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Kathy Merlo has disclosed no relevant financial relationships.

Andrew D. Bowser, ELS, CHCP

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Andrew D. Bowser, ELS, CHCP has disclosed the following relevant financial relationships:
Spouse served as an advisor or consultant for CSL Behring and Pharming
Spouse served as a speaker for Shire/Takeda

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Making the Case for an Opioid Action Plan: The Role of Naloxone

Authors: Steven Stanos, DO; Kathleen Hanley, MD; Kevin L. Zacharoff, MD
CME / ABIM MOC / CE Released: 3/17/2021; Reviewed and Renewed: 3/17/2022
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/17/2023, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, anesthesiologists, and primary care physicians.

The goal of this activity is to inform clinicians about the prophylactic prescription of naloxone for patients who are appropriately prescribed an opioid analgesic.

Upon completion of this activity, participants will:

Have increased knowledge regarding
- The factors associated with an increased risk of overdose in patients receiving an appropriate prescription for an opioid analgesic
- Guidance for the coprescription of naloxone with an opioid analgesic for the management of pain
Have greater competence related to
- The identification of patients who are candidates for the prophylactic use of naloxone

Disclosures

Moderator

Steven Stanos, DO

Pain Medicine Specialist
Swedish Health System
Swedish Pain Services
Seattle, Washington

Disclosures

Disclosure: Steven Stanos, DO, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Emergent BioSolutions; Hisamitsu; Lilly; Pfizer; Vertex

Panelists

Kathleen Hanley, MD

Associate Professor
Department of Medicine
NYU Grossman School of Medicine
New York, New York

Disclosures

Disclosure: Kathleen Hanley, MD, has disclosed no relevant financial relationships.

Kevin L. Zacharoff, MD

Faculty and Clinical Instructor
Course Director of Pain and Addiction
Department of Family, Population, and Preventive Medicine
Renaissance School of Medicine at Stony Brook University
Stony Brook, New York

Disclosures

Disclosure: Kevin L. Zacharoff, MD, has disclosed no relevant financial relationships.

Editors

Kathy Merlo

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Kathy Merlo has disclosed no relevant financial relationships.

Andrew D. Bowser, ELS, CHCP

Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Andrew D. Bowser, ELS, CHCP has disclosed the following relevant financial relationships:
Spouse served as an advisor or consultant for CSL Behring and Pharming
Spouse served as a speaker for Shire/Takeda

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-21-257-H08-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME / ABIM MOC / CE

Making the Case for an Opioid Action Plan: The Role of Naloxone

Authors: Steven Stanos, DO; Kathleen Hanley, MD; Kevin L. Zacharoff, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 3/17/2021; Reviewed and Renewed: 3/17/2022

Valid for credit through: 3/17/2023, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC / CE Information

Activity Transcript

PDF Downloads

For Your Patient

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Steven Stanos, DO

Panelists

Kathleen Hanley, MD

Kevin L. Zacharoff, MD

Editors

Kathy Merlo

Andrew D. Bowser, ELS, CHCP

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Making the Case for an Opioid Action Plan: The Role of Naloxone

Target Audience and Goal Statement

Disclosures

Moderator

Steven Stanos, DO

Panelists

Kathleen Hanley, MD

Kevin L. Zacharoff, MD

Editors

Kathy Merlo

Andrew D. Bowser, ELS, CHCP

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Making the Case for an Opioid Action Plan: The Role of Naloxone

PDF Downloads